111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
液基细胞学（TCT）联合人乳头瘤病毒（HPV）DNA检测筛查宫颈上皮内病变：一种分流策略
Authors Song M, Mao M, Zhao H, Chen C
Received 4 September 2025
Accepted for publication 10 December 2025
Published 16 December 2025 Volume 2025:17 Pages 5487—5495
DOI https://doi.org/10.2147/IJWH.S565280
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Everett Magann
Meiyu Song, Minhong Mao, Huirong Zhao, Chen Chen
Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100043, People’s Republic of China
Correspondence: Meiyu Song, Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, No. 5, Jingyuan Road, Shijingshan District, Beijing, 100043, People’s Republic of China, Email songmeiyu2016@163.com
Objective: To explore the value of the ThinPrep cytology test (TCT) combined with human papillomavirus (HPV) DNA detection in the screening and triage of cervical lesions.
Methods: A total of 1671 patients with cervical inflammation or lesions who underwent colposcopy and biopsy between April 2020 and December 2022 were analyzed. The data included TCT, HPV DNA, and pathological findings.
Results: The incidence of high-grade squamous intraepithelial lesions (HSILs) or above significantly increased with TCT severity: 25.9% in the negative for intraepithelial lesion or malignancy (NILM) group, 39.4% in the atypical squamous cells of undetermined significance (ASCUS) and low-grade SIL (LSIL) groups, and 76.5% in the HSIL+ group (P< 0.001 for all pairwise comparisons). The incidence also varied significantly by HPV status: 58.2% in the HPV 16 or 18 group, 28.6% in the other high-risk groups, and 17.6% in the low-risk and negative groups (P< 0.001 for all pairwise comparisons). Multivariate analysis revealed independent risk factors for HSIL+: younger age (OR=0.972), HSIL and above cytology (OR=10.154), ASCUS and LSIL cytology (OR=2.250), HPV 16/18 infection (OR=8.061), and other high-risk HPV infections (OR=2.578). Patients with concurrent HPV 16/18 infection and HSIL or above cytology presented a substantially elevated risk (OR=41.517). Among the cohort, 35 cases of cervical squamous cell carcinoma were identified.
Conclusion: TCT combined with HPV DNA testing provides an effective strategy for risk stratification in cervical screening. Our findings support that patients with HPV16 or 18 should be referred directly for colposcopy, and patients with other high-risk HPV types and TCT results of ASCUS and above are also recommended for colposcopy referrals. These referral suggestions warrant further validation in larger, multicenter studies.
Keywords: cervical cancer, precancerous lesions, ThinPrep cytology test, HPV DNA detection, colposcopy referral, risk stratification
Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100043, People’s Republic of China
Correspondence: Meiyu Song, Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, No. 5, Jingyuan Road, Shijingshan District, Beijing, 100043, People’s Republic of China, Email songmeiyu2016@163.com
Objective: To explore the value of the ThinPrep cytology test (TCT) combined with human papillomavirus (HPV) DNA detection in the screening and triage of cervical lesions.
Methods: A total of 1671 patients with cervical inflammation or lesions who underwent colposcopy and biopsy between April 2020 and December 2022 were analyzed. The data included TCT, HPV DNA, and pathological findings.
Results: The incidence of high-grade squamous intraepithelial lesions (HSILs) or above significantly increased with TCT severity: 25.9% in the negative for intraepithelial lesion or malignancy (NILM) group, 39.4% in the atypical squamous cells of undetermined significance (ASCUS) and low-grade SIL (LSIL) groups, and 76.5% in the HSIL+ group (P< 0.001 for all pairwise comparisons). The incidence also varied significantly by HPV status: 58.2% in the HPV 16 or 18 group, 28.6% in the other high-risk groups, and 17.6% in the low-risk and negative groups (P< 0.001 for all pairwise comparisons). Multivariate analysis revealed independent risk factors for HSIL+: younger age (OR=0.972), HSIL and above cytology (OR=10.154), ASCUS and LSIL cytology (OR=2.250), HPV 16/18 infection (OR=8.061), and other high-risk HPV infections (OR=2.578). Patients with concurrent HPV 16/18 infection and HSIL or above cytology presented a substantially elevated risk (OR=41.517). Among the cohort, 35 cases of cervical squamous cell carcinoma were identified.
Conclusion: TCT combined with HPV DNA testing provides an effective strategy for risk stratification in cervical screening. Our findings support that patients with HPV16 or 18 should be referred directly for colposcopy, and patients with other high-risk HPV types and TCT results of ASCUS and above are also recommended for colposcopy referrals. These referral suggestions warrant further validation in larger, multicenter studies.
Keywords: cervical cancer, precancerous lesions, ThinPrep cytology test, HPV DNA detection, colposcopy referral, risk stratification